15:27 , Jun 8, 2018 |  BC Week In Review  |  Company News

Opthotech gains gene therapy for ophran vision-loss disease

Ophthotech Corp. (NASDAQ:OPHT) acquired exclusive, worldwide rights to develop and commercialize a preclinical ophthalmic gene therapy from the University of Florida Research Foundation and the University of Pennsylvania. The deal gives the biotech an adeno-associated virus...
20:58 , Jun 7, 2018 |  BC Extra  |  Company News

Ophthotech gains gene therapy for orphan vision-loss disease

Ophthotech Corp. (NASDAQ:OPHT) gained $0.29 (10%) to $3.09 on Thursday on news that it acquired exclusive, worldwide rights to develop and commercialize a preclinical ophthalmic gene therapy from the University of Florida Research Foundation and...
21:48 , Mar 9, 2018 |  BC Extra  |  Company News

CRISPR one step closer to EU trial this year

CRISPR Therapeutics AG (NASDAQ:CRSP) added $3.02 to $56.72 on Friday after it said in its earnings that the first clinical trial application (CTA) for its ex vivo gene therapy CTX001 has been accepted in Europe....
04:14 , Dec 8, 2017 |  BC Week In Review  |  Financial News

Editas raises $50M in follow-on

Gene editing company Editas Medicine Inc. (NASDAQ:EDIT) said it raised about $50 million through the sale of 1.97 million shares in a follow-on underwritten by Morgan Stanley. In March, the company granted Allergan plc (NYSE:AGN) an...
00:10 , Dec 7, 2017 |  BC Extra  |  Financial News

Editas raises $50M follow-on

Gene editing company Editas Medicine Inc. (NASDAQ:EDIT) said it raised about $50 million through the sale of 1.97 million shares in a follow-on underwritten by Morgan Stanley. Editas did not respond to an inquiry regarding...
23:35 , Dec 5, 2017 |  BC Extra  |  Financial News

Editas proposes $50M follow-on

Gene editing company Editas Medicine Inc. (NASDAQ:EDIT) proposed to raise $50 million in a follow-on underwritten by Morgan Stanley. Editas, which proposed the offering after market close Tuesday, was off $0.47 to $27.29 on the...
21:49 , Dec 1, 2017 |  BC Week In Review  |  Financial News

ProQR Therapeutics raises $20M

ProQR Therapeutics N.V. (NASDAQ:PRQR) raised $20 million on Nov. 14 through the sale of 5 million shares in a public offering and 1.4 million shares in a concurrent registered direct offering, each at a price...
22:01 , Sep 28, 2017 |  BC Innovations  |  Tools & Techniques

Proofreading the editors

The threat of off-target edits has spurred CRISPR companies to build in quality control systems from the earliest stages of drug development. Editas Medicine Inc. thinks its Uni-Directional Targeted Sequencing methodology, dubbed “UDiTaS,” will detect...
18:40 , May 18, 2017 |  BC Week In Review  |  Clinical News

Editas delays IND submission for LCA10

In its 1Q17 earnings report, Editas Medicine Inc. (NASDAQ:EDIT) said it delayed its target date to submit an IND for LCA10 from the end of 2017 to mid-2018. The preclinical CRISPR-based product is designed to...
19:10 , May 16, 2017 |  BC Extra  |  Clinical News

New technologies in focus at ASGCT

ToolGen Inc. (KONEX:199800), Editas Medicine Inc. (NASDAQ:EDIT) and Selecta Biosciences Inc. (NASDAQ:SELB) each spotlighted new technologies and techniques at the American Society for Gene and Cell Therapy (ASGCT) meeting in Washington, D.C. ToolGen Inc. showed CRISPR-based...